The Food and Drug Administration announced traditional approval of Johnson & Johnson’s Darzalex Faspro with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis. The FDA granted accelerated approval for this indication in 2021.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Zymeworks announces strategic initiative to optimize Ziihera cash flows
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Midday Fly By: Berkshire takes Alphabet stake, J&J buying cancer drug maker
- M&A News: Johnson & Johnson Stock (JNJ) Perks Up as it Lands $3B “Hold and Kill” Cancer Deal
- Johnson & Johnson to acquire Halda Therapeutics for $3.05B in cash